Synmosa Biopharma Corporation
Research Synmosa Biopharma Corporation (4114.TWO) on Bullrun: market cap TWD 15.46B, P/E 19.4, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4114.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 15.46B
- P/E19.4
- Dividend yield3.1%
- Financial periodQ2 2026
- RevenueTWD 1.92B
- Net incomeTWD 238.58M
- Free cash flow-TWD 232.50M
- Gross margin38.8%
Valuation Snapshot
latest market cap is TWD 15.46B; P/E is 19.4; dividend yield is 3.1%.
Peer valuation comparison
Latest P/E is 19.42x versus a Healthcare sector median of 21.8x (10.9% below).
Latest dividend yield is 3.06% versus a Healthcare sector median of 2.4% (27.5% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 15.46B | 19.4 | 2.8% | 0.85 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.85 TWD, yield 3.1%.
About Synmosa Biopharma Corporation
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays.
ETFs that hold Synmosa Biopharma Corporation
US-listed ETFs
Synmosa Biopharma Corporation is held by 14 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | 0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Synmosa Biopharma Corporation's market cap?
Synmosa Biopharma Corporation's market capitalization is TWD 15.46B.
What is Synmosa Biopharma Corporation's P/E ratio?
Synmosa Biopharma Corporation's price-to-earnings (P/E) ratio is 19.4.
Does Synmosa Biopharma Corporation pay a dividend?
Synmosa Biopharma Corporation has a dividend yield of 3.1%.
What does Synmosa Biopharma Corporation do?
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays.